What is Injectable Seizure Drugs Market Scope?
Seizures, a major symptom of epilepsy, are defined as abnormal paroxysmal electrical disorders of cortical neural networks. Many anti-epileptic drugs work in some way by reducing neuronal excitability (sodium and calcium channel modulation) or increasing the inhibition of neurons by interacting in different parts of am-aminobutyric acid receptors. It is believed that many injectable seizure drugs act as a result of several simultaneous processes in both the excitatory and inhibitory structures. Epilepsy affects nearly 3 million people in the United States, with nearly 500 new cases of epilepsy being diagnosed each day. The median incidence of acute symptomatic seizures is 29–39 per 100,000 per year. Given the increasing number of epileptic seizures due to greater exposure to perinatal risk factors and a higher rate of CNS disease, the injectable seizure market is the leading dosage form choice for treating seizures. Injectable seizure medications are important in treating emergencies of clinical seizure emergencies and in other treatments that cannot be administered orally. The injectable seizure medications provide quick and complete delivery (through blood vessels) or near-complete (muscle building) bioavailability. Controlled administration of the injectable seizure medication is possible with intravenous, but not intramuscular, formulations.
The Injectable Seizure Drugs market study is being classified by Type (Fosphenytoin, Midazolam, Carbamazepine, Cenobamate, Gabapentin, Phenytoin, Lamotrigine, Topiramate, Levetiracetam, Clobazam, Diazepam and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Injectable Seizure Drugs market throughout the predicted period.
Sanofi (France), Pfizer Inc. (United States), GW Pharmaceuticals plc (United Kingdom), UCB S.A. (Belgium), Eisai Co.Ltd. (Japan), Sunovion Pharmaceuticals Inc. (United States), H. Lundbeck A/S (Denmark), GlaxoSmithKline plc (United Kingdom), Sandoz Inc. (Germany), Omega Laboratories Ltd (United States), Fresenius Kabi (Germany), Mylan Pharmaceuticals (United States) and Roche Holding AG (Switzerland) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Injectable Seizure Drugs market by Type, Application and Region.
On the basis of geography, the market of Injectable Seizure Drugs has been segmented into .
Xeris Pharma had received FDA approval for its diazepam formulation for the treatment of acute repetitive seizures, also known as cluster seizures, for Phase III clinical trial. and Sedor Pharmaceuticals, LLC, had received FDA approval for fosphenytoin sodium for injection in status epilepticus in adult and pediatric patients.
Influencing Market Trend
- The Rising Demand for Preventing or Controlling Epileptic Seizures
- Improvement in Health Care Reforms
- Increasing Acceptance of Novel and Cost-Effective Treatments
- The Rising Prevalence of Seizures
- Increasing Cases of Accidents and Injuries
- The Rising Patient Awareness Regarding Effective Treatment of Epilepsy
- A Rise in Investment in Research Activities to Develop More Injectable Seizure Drugs
- The Growing Pharmaceutical Companies
- The Illicit Use of Anti-Seizure Drugs
- The Least Awareness of the Seizure as a Disorder
- Stringent Regulations and the Lack of FDA Approvals in Some Regions
- Marketing Of an Unapproved Drug
- Recall of Drug by the FDA
Key Target AudienceVenture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Injectable Seizure Drugs, Government Regulatory and Research Organizations and End-Use Industries
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Frequently Asked Questions (FAQ):
1. At what growth rate would the Injectable Seizure Drugs market expands?
The Global Injectable Seizure Drugs market is expected to see a growth of % during projected year 2020 to 2026.
2. Who are the prominent players of the Global Injectable Seizure Drugs market?
The prominent players of Global Injectable Seizure Drugs market are Sanofi (France), Pfizer Inc. (United States), GW Pharmaceuticals plc (United Kingdom), UCB S.A. (Belgium), Eisai Co.Ltd. (Japan), Sunovion Pharmaceuticals Inc. (United States), H. Lundbeck A/S (Denmark), GlaxoSmithKline plc (United Kingdom), Sandoz Inc. (Germany), Omega Laboratories Ltd (United States), Fresenius Kabi (Germany), Mylan Pharmaceuticals (United States) and Roche Holding AG (Switzerland), to name a few.
3. What are the top priorities to focus for Injectable Seizure Drugs market’s growth?
In this highly competitive & fast evolving Injectable Seizure Drugs industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.